西拉普利(Cilazapril,Ro31-2848)是一种新型非巯基血管紧张素转换酶(ACE)抑制剂。本文扼要综述其药理与临床试验。 Holck等报道,清醒的肾性高血压犬口服西拉普利每日2×10mg/kg,动脉收缩压从145±5降至106±7mmHg(39±6mmHg),作用持续24小时以上,重复应用降压作用不减,心率仅有轻微增加。麻醉犬血流动力学研究表明,静注本品1mg/kg,总外周血管阻力、心输出量,血压分别降低12%、16%和27%。血浆肾素活性增加(0分钟时为 Cilazapril (Ro31-2848) is a novel non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor. This article summarizes its pharmacology and clinical trials. Holck et al reported that sober renal hypertensive dogs oral cilazapril daily 2 × 10mg / kg, arterial systolic blood pressure decreased from 145 ± 5 to 106 ± 7mmHg (39 ± 6mmHg), the role lasts for 24 hours or more, repeated application Antihypertensive effect diminished, only a slight increase in heart rate. Anesthetic dogs hemodynamics study showed that the intravenous injection of 1mg / kg, total peripheral vascular resistance, cardiac output, blood pressure decreased by 12%, 16% and 27%. Plasma renin activity increased (0 minutes